Healthcare
Hua Medicine (Shanghai) Ltd.(HUMDF)
Live Price
Offline$0.3401
-17.19% today
1Y Change
-17.19%
Window
Jun 25, 2025 → Jun 17, 2026
- Market Cap
- $2.88B
- Revenue Growth
- +87.7%
- EPS Growth
- +548.0%
- Dividend Yield
- 0.0%
Coverage: 252 bars · Jun 25, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hua Medicine (Shanghai) Ltd. (HUMDF) is a Healthcare stock with a market cap of $2.88B and listed on OTC. The stock last traded around $0.34 and down 17.2% across the available one-year price window (Jun 25, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +87.7%, EPS growth of +548.0%, a dividend yield of 0.0%. What stands out right now is revenue +87.7%, EPS +548.0%, free cash flow +85.8% with operating margin -29.4% and ROIC -11.0%. Valuation is more restrained than many high-expectation growth names at P/E 2.8 and price/sales 5.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines HUMDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+87.7% vs +7.6% peer median
Operating Margin
Below sector median
-29.4% vs +19.4% peer median
P/E
Below sector median
2.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +87.7% and EPS at +548.0%, with operating margin around -29.4%.
Benchmark Edge
HUMDF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HUMDF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HUMDF Max Drawdown
-27.98%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HUMDF and SPY.
Company Overview
Hua Medicine (Shanghai) Ltd.
Other OTC
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
- Leadership
- Li Chen
- IPO Date
- Mar 15, 2021
- Employees
- 168
- Street Address
- Building A
- Mailing
- Shanghai
- Region
- Shanghai, CN
- Reporting Currency
- USD
- Investor Line
- +86 21 5886 5599
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 2.8
- EV/EBITDA
- —
- Price/Sales
- 5.9
- Price/Book
- 3.1
Growth
- Revenue
- +87.7%
- EPS
- +548.0%
- Free Cash Flow
- +85.8%
Profitability
- Gross Margin
- 56.9%
- Operating Margin
- -29.4%
- Net Margin
- 226.8%
- ROE
- 107.2%
- ROIC
- -11.0%
Balance Sheet
- Debt/Equity
- 0.30
- Current Ratio
- 6.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.